Articles By Rob Wright, Chief Editor 2011-2021
-
![Teamwork]( "Are We On The Precipice Of Unprecedented Collaboration In Biopharma?")
Are We On The Precipice Of Unprecedented Collaboration In Biopharma?1/28/2021The recent announcement of Sanofi agreeing to help produce Pfizer's COVID-19 vaccine could represent biopharma's entry into a period of unprecedented collaboration.
-
![JPMBLogphoto]( "Let’s Talk About JPM 2021")
Let’s Talk About JPM 20211/19/2021Rob Wright, chief editor of Life Science Leader, shares thoughts on attending the 39th Annual J.P. Morgan Healthcare Conference (JPM) which was 100% virtual this year.
-
![targetbullseyeaccuracy450x300]( "What Went Right In 2020? My Top 5 List")
What Went Right In 2020? My Top 5 List1/5/2021Life Science Leader's Rob Wright reviews five things that went right in 2020.
-
![Frank Gupton_450x300.jpg]( "Frank Gupton – Revolutionizing Pharma Manufacturing From The Outside In")
Frank Gupton – Revolutionizing Pharma Manufacturing From The Outside In1/4/2021“I’ve gotten more press during the last six and a half months than in my 68 years on this earth,” jokes Frank Gupton, Ph.D., a professor at Virginia Commonwealth University who has been involved in some key recent developments in pharma manufacturing.
-
![feature_Oysterpoint_450x300]( "How A First-Time Pharma CEO Faces Hypergrowth")
How A First-Time Pharma CEO Faces Hypergrowth1/4/2021Jeffrey Nau, Ph.D., discusses the career path that led him to becoming president and CEO of Oyster Point Pharma, a publicly traded biopharma now valued at more than $550 million and on the brink of commercial launch.
-
![Rob Wright 2017]( "New Year, New President, New Outlook")
New Year, New President, New Outlook1/4/2021New Year’s is not just a time of celebration, but a point at which we step out of the day-to-day to reflect on how we did — and resolve to do better.
-
![Finance Outlook Bucket_450x300.jpg]( "What Do 10 Biopharma Finance Experts Expect for 2021?")
What Do 10 Biopharma Finance Experts Expect for 2021?12/1/2020We invited 10 biopharmaceutical industry finance experts to provide their perspectives on everything from remote work, to supply chains, to the reshoring of U.S. biopharmaceutical manufacturing operations.
-
![Manufacturing Outlook bucket_450x300.jpg]( "The Future Of Biopharma Manufacturing Has Never Been More Critical")
The Future Of Biopharma Manufacturing Has Never Been More Critical12/1/2020Here’s what six biopharmaceutical manufacturing executives have to say on emerging manufacturing innovations, key trends to pay attention to in 2021 (and beyond), and so much more.
-
![Rob Wright 2017]( "What’s The Annual Outlook For Life Sciences In 2021?")
What’s The Annual Outlook For Life Sciences In 2021?12/1/2020As we’ve done previously, this year we posed many questions to lots of executives across a variety of life science industry disciplines, and here you will gain perspectives on what to expect on biosimilars to outsourcing, and everything in between.
Rob Wright
Rob Wright was chief editor of Life Science Leader magazine from 2011-2021. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL